Skip to content Skip to footer
Merck (MRK), ever the discerning giant of Big Pharma, has decided to join the prophylactic party by acquiring Cidara Therapeutics (CDTX) for a headline-grabbing $9.2 billion—a move that whispers both “strategic pipeline expansion” and “Keytruda’s patent clock is ticking, folks.” In a…